Global In Vivo Toxicology Market Size By Testing Facility (Out-Source Testing Facility and In-House Testing Facility), By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations), By Toxicity End Point (Immunotoxicity, Systemic Toxicity, Genotoxicity), By Test Type (Acute, Sub-Acute, Sub-Chronic, Chronic), By Product (Instruments and

In Vivo Toxicology Market Size And Forecast

In Vivo Toxicology Market size was valued at USD 6.25 Billion in 2024 and is projected to reach USD 9.11 Billion by 2031, growing at a CAGR of 5.31% from 2024 to 2031.

Development of exclusive In Vivo Toxicology tests, increasing R&D activities in the pharmaceutical industry, innovations in animal models and the growing demand for personalized medicine are the primary drivers of the growth of the market. The Global In Vivo Toxicology Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global In Vivo Toxicology Market Definition

The scientific studies performed within an intact, living organism such as a laboratory animal, to understand the toxic effects of various chemical substances administered in the test subject are called In Vivo Toxicology. Rats, mice, rabbits, guinea pigs, hamsters, etc. are the various test subjects on which these chemicals can be administered. These test subjects can be exposed to these chemical substances in a variety of ways, such as oral, intravenous, intraperitoneal, intramuscular, and subcutaneous.

Non-clinical (or preclinical) toxicology studies are essential to have a detailed understanding of the toxicological profiles of new drug candidates prior to human exposure and improvise the existing profile of various drugs, for instance, new indications, new formulations, new routes of administration, etc. Non-clinical toxicology studies vary in length (e.g., acute, subchronic, chronic) depending on the length of exposure in the clinical trial that they support. It is important to have a thorough knowledge of a drug’s efficacy, safety, and mechanism of action (MOA) prior to its release in the market.

The establishment of efficacy is critical so that the drug yields positive results on a maximum number of people that administer the drugs upon them. In vivo animal models are used for research work to minimize the adverse side effects and maximize the therapeutic properties of a drug before it is taken for clinical trials. Genetically engineered mouse models play a critical role in the process of drug discovery. Research on these genetically engineered mouse models facilitates the study and characterization of disease pathology, target identification, and in vivo evaluation of novel therapeutic agents and treatments.

Global In Vivo Toxicology Market Overview

What's really fueling the growth of the Global In Vivo Toxicology Market? Well, it's all about boosting R&D efficiency. More and more pharma companies and medical device makers are laser-focused on innovating and getting more bang for their R&D buck. The healthcare landscape is changing, too. With more people around the world needing medical care, drug companies are under pressure to develop medications that can fight diseases without causing nasty side effects. But let's be real, R&D is risky. In the U.S., only a tiny fraction of drugs – like, 5 out of 5000 – even make it to the point where they can be tested on people. Getting more drugs approved in Phase I trials is a top priority, and that means a ton of R&D happens early in the development process, even before those super expensive clinical trials. Because of this, we're likely to see an increase in In Vivo Toxicology activities, and that should really give the market a boost.

According to the BIO back in 2019, emerging growth companies (EGCs) in the U.S. are really driving innovation. They're responsible for about 82.7% of all venture capital investments in research and development for new therapies and drugs over the past decade! Now, even though the COVID-19 outbreak has been tough on a lot of industries, it's actually been a boost for the In Vivo Toxicology Market. Why? Because everyone's scrambling to develop effective vaccines! So many drugs are in the pre-clinical and clinical trial phases. The NY Times reports that researchers are currently putting 89 vaccines through the paces in human clinical trials, with 23 already in the final stretch. Plus, at least 77 more vaccines are being actively studied in animals. All this testing has created a huge demand for different animal models to understand the virus's effects, which has fueled growth in the Global In Vivo Toxicology Market.

When it comes to studying COVID-19, the K18-hACE2 transgenic mouse is a real star. But it's not the only one! Researchers also use AC70 transgenic mice and hCAE2 Tg mice to see how the virus affects them. For a faster and more reliable way to study SARS-CoV-2, the Adeno-associated virus (AAV) delivery-based mouse model has become popular. And let's not forget about the trusty BALB/c and C57BL/6 mice strains. Besides mice, the Golden Syrian Hamster is another good option for COVID-19 research. But here's the thingeveryone wants them right now, and there just aren't enough to go around. Another challenge is the push to reduce animal testing. This has led to the exploration of alternatives like In Vitro Tests, which involve studying isolated tissues in a controlled lab setting – basically, testing outside of a living organism.

Think of Ex Vivo Tests as experiments on tissues from an animal or organism, trying to keep things as natural as possible. Then you've got In Silico tests, which are all about running computer simulations. Doctors and patients are catching on to the advantages of In Vivo testing, and that's expected to really boost the Global In Vivo Toxicology Market. Plus, we're seeing more "humanized" animal models that help us study tough diseases like HIV/AIDS, Cancer, and Hepatitis, which should also help the market grow. When it comes to mammalian models, little guys like mice and rats are popular because they're easy to care for, reproduce quickly, and even share some genetic similarities with us, making them easy to genetically manipulate for research.

Global In Vivo Toxicology MarketSegmentation Analysis

The Global In Vivo Toxicology Market is segmented based on Testing Facility, End User, Toxicity End Point, Test Type, Product, and Geography.

In Vivo Toxicology Market, By Testing Facility

• Out-Sourced Testing Facility• In-House Testing Facility

Based on Testing Facility, the market is segmented into Out-Source Testing Facility and In-House Testing Facility. The outsourced testing facilities held a large market segment in 2019, and this large market share is expected to continue in the forecast period. This is because outsourcing to CRO’s (Contract Research Organizations) is more cost-effective for pharmaceutical companies.

In Vivo Toxicology Market, By End User

• Academic and Research Institutes• Pharmaceutical and Biotechnology Companies• Contract Research Organizations• Other End Users

Based on End User, the market is segmented into Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Other End Users. The academic and research institutes segment accounted for the largest share of the In Vivo Toxicology Market in 2019. This market prevalence can be attributed to a growing number of academic researches in the field of In Vivo Toxicology, coupled with funding to the academic and research institutes to conduct In Vivo Toxicology research.

In Vivo Toxicology Market, By Toxicity End Point

• Immunotoxicity• Systemic toxicity• Carcinogenicity• Genotoxicity• Developmental & reproductive toxicity (DART)• Other toxicity Endpoints

Based on Toxicity End Point, the market is segmented into Immunotoxicity, Systemic Toxicity, Carcinogenicity, Genotoxicity, Developmental and Reproductive Toxicity (DART), and Other Toxicity Endpoints. Other Toxicity Endpoints, namely, Organ Toxicity, Skin Irritations, Endocrine, Juvenile Toxicity, Disruptor Toxicity, Phototoxicity, Ocular Toxicity, and Others. Immunotoxicity accounted for the largest share of the global In Vivo Toxicology Market. It was followed by the systemic toxicity segment. Growing demand for Biologic Drugs (Drugs produced from Living Organisms) and Biosimilars (An appropriately approved variant of a certain Biologic) is driving the growth of the immunotoxicity segment.

In Vivo Toxicology Market, By Test Type

• Acute• Sub-Acute• Sub-Chronic• Chronic

Based on Test Type, the market is segmented into Acute, Sub-Acute, Sub-Chronic, and Chronic. Chronic and Sub-Chronic segments led the market respectively in that order in 2019, owing to the increasing demand for medicinal drugs used for the treatment of diseases that persist over the long term like Cancer, Arthritis, Convulsions, and Hypertension.

In Vivo Toxicology Market, By Product

• Instruments• Consumable

Based on Product, the market is segmented into Instruments and Consumables. Consumables are further divided into Reagents and Kits and Animal models on the basis of Product. Consumables are the market leaders in this segment and their dominance is expected to persist over the forecast period owing to the high growth of Animal Model demands, in addition to an incremental R&D expenditure on the healthcare sector globally.

In Vivo Toxicology Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global In Vivo Toxicology Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America has been a dominant region in the market owing to its technological leadership and the presence of major players such as Danaher, Thermo Fischer, Jackson in this region.

Key Players

The “Global In Vivo Toxicology Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Danaher Corporation (U.S.), Envigo (U.S.), Charles River Laboratories (U.S.), Waters Corporations (U.S.), Bruker Corporation (U.S.), Transcure BioServices SAS (France), GenOway S.A. (France), Harbour BioMed (U.S.), Merck KGaA (Germany), and GVK Biosciences Pvt. Ltd. (India).

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Harbour BioMed (HBM) on March 2021 announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors.

• On 31st March 2020, Danaher Corporation announced the completion of its acquisition of the Biopharma business from General Electric Company’s Life Sciences division. The business was named Cytiva and will be a standalone operating company within Danaher’s Life Sciences segment.

• Thermo Fisher Scientific Inc, the world leader in serving science, today announced the launch of the Thermo Scientific AerosolSense Sampler, a new surveillance solution designed to deliver fast and highly reliable insight into the presence of in-air pathogens, including SARS-CoV-2.

• Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio through the Jh Mouse Model.

• On the 13th of April 2021, Waters Corporation and Genovis AB (Nasdaq First North Growth Market) formally announced a collaboration to develop and market complete routine biopharmaceutical characterization workflows based on the Waters™ BioAccord™ LC-MS System, Andrew+ pipetting robot, and Genovis SmartEnzymes™. The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing, and quality control (QC).

Report Scope

Research Methodology of Market Research